Cargando…
Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma
Multikinase inhibitors (MKI) and mammalian target of rapamycin (mTOR) inhibitors prolong progression-free (PFS) and overall survival (OS) in the treatment of metastatic renal cell carcinoma (mRCC) by reducing angiogenesis and tumor growth. In this regard, the MKI lenvatinib and the mTOR inhibitor ev...
Autores principales: | Bendtsen, Mathias Alrø Fichtner, Grimm, Daniela, Bauer, Johann, Wehland, Markus, Wise, Petra, Magnusson, Nils E., Infanger, Manfred, Krüger, Marcus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5578126/ https://www.ncbi.nlm.nih.gov/pubmed/28796163 http://dx.doi.org/10.3390/ijms18081736 |
Ejemplares similares
-
Drug-Induced Hypertension Caused by Multikinase Inhibitors (Sorafenib, Sunitinib, Lenvatinib and Axitinib) in Renal Cell Carcinoma Treatment
por: Bæk Møller, Nanna, et al.
Publicado: (2019) -
Biomarkers for Anti-Angiogenic Therapy in Cancer
por: Wehland, Markus, et al.
Publicado: (2013) -
The Vasoactive Mas Receptor in Essential Hypertension
por: Povlsen, Amalie L., et al.
Publicado: (2020) -
The Adverse Effect of Hypertension in the Treatment of Thyroid Cancer with Multi-Kinase Inhibitors
por: Ancker, Ole Vincent, et al.
Publicado: (2017) -
Pazopanib, Cabozantinib, and Vandetanib in the Treatment of Progressive Medullary Thyroid Cancer with a Special Focus on the Adverse Effects on Hypertension
por: Milling, Rikke Vilsbøll, et al.
Publicado: (2018)